心脉医疗(688016) - 2024 Q1 - 季度财报

Financial Performance - The net profit attributable to shareholders of the listed company increased by 47.62% compared to the same period last year[15]. - The net profit attributable to shareholders after deducting non-recurring gains and losses increased by 48.91%[15]. - The company's operating revenue for the reporting period was ¥358,081,405.15, representing a year-on-year increase of 25.38%[34]. - The net profit attributable to shareholders was ¥184,296,095.55, reflecting a growth of 47.62% compared to the same period last year[34]. - The basic earnings per share (EPS) was ¥2.23, up by 28.90% from the previous year[34]. - Total operating revenue for Q1 2024 reached RMB 358,081,405.15, a 25.4% increase from RMB 285,591,399.25 in Q1 2023[48]. - Net profit attributable to shareholders of the parent company was RMB 184,296,095.55, up from RMB 124,840,722.70, marking a 47.5% growth year-over-year[51]. - Basic and diluted earnings per share for Q1 2024 were both RMB 2.23, compared to RMB 1.73 in Q1 2023, indicating a 28.9% increase[51]. Cash Flow - The net cash flow from operating activities increased by 77.53% due to business scale growth and improved cash flow management[15]. - The company's cash flow from operating activities for Q1 2024 was approximately ¥211.95 million, an increase of 77.5% compared to ¥119.39 million in Q1 2023[29]. - The net cash flow from investing activities was -¥1,737,334,030.87, indicating a significant outflow compared to -¥22,140,416.31 in the same period last year[30]. - The net cash flow from financing activities was ¥31,649,321.21, a recovery from -¥3,135,992.11 in the previous year[30]. Research and Development - Research and development expenses decreased by 22.53% compared to the previous period, reflecting an optimization of the R&D team structure[16]. - The proportion of R&D expenses to operating income decreased by 8.14 percentage points, indicating a focus on improving R&D output efficiency[16]. - Research and development (R&D) expenses totaled ¥47,137,794.16, which is a decrease of 22.53% year-on-year[35]. - The R&D expenses as a percentage of operating revenue were 13.16%, down by 8.14 percentage points from the previous year[35]. - Research and development expenses decreased to RMB 23,190,117.20 from RMB 36,218,269.91, a reduction of 36.1%[50]. Shareholder Information - The total number of common shareholders at the end of the reporting period was 10,443[8]. - The largest shareholder, Endovascular CHINA Corp. Limited, holds 39.77% of the shares[8]. - The company’s total liabilities and equity structure remains stable, with no significant changes reported in the shareholder composition[21]. Assets and Liabilities - Total current assets as of March 31, 2024, amounted to ¥3.63 billion, up from ¥3.37 billion as of December 31, 2023, reflecting a growth of 7.9%[24]. - The total non-current assets as of March 31, 2024, were ¥122.98 million, slightly up from ¥121.86 million as of December 31, 2023, reflecting a growth of 0.92%[24]. - The company's cash and cash equivalents decreased to ¥1.47 billion as of March 31, 2024, from ¥2.97 billion as of December 31, 2023, a decline of 50.3%[24]. - The company’s accounts receivable increased to ¥193.34 million as of March 31, 2024, compared to ¥148.09 million as of December 31, 2023, representing a growth of 30.5%[24]. - Total assets at the end of the reporting period amounted to ¥4,524,504,555.34, a 6.55% increase from the end of the previous year[35]. - The total equity attributable to shareholders increased to ¥4,042,715,729.63, marking a 5.17% rise compared to the previous year[35]. Other Financial Metrics - The company recognized a government subsidy of 2,396,063.50 yuan during the reporting period[6]. - The weighted average return on net assets decreased by 2.49 percentage points due to the receipt of funds from a private placement in December 2023[15]. - The company reported a total non-recurring gains of 6,269,178.62 yuan after tax adjustments[14]. - Tax expenses rose to RMB 33,894,586.82 from RMB 21,375,906.54, representing a 58.7% increase[50]. - Investment income increased significantly to RMB 7,127,681.04 from RMB 2,164,491.69, a growth of 229.5%[50]. - Other comprehensive income attributable to shareholders of the parent company showed a loss of RMB 35,100.64, compared to a gain of RMB 4,360.05 in the previous year[51]. - The company did not apply new accounting standards for the first quarter of 2024[54].